SCHEMBL6824675

SCHEMBL6824675

CCOC(=O)c1nc2cc(Cl)ccc2cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.54
MAPK1 P28482 2/20 0.54
KMT2A Q03164 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
ALOX15 P16050 1/20 0.50
GLP1R P43220 1/20 0.48
TARBP2 Q15633 1/20 0.48
GABRA2 P47869 4/20 0.45
GABRB2 P47870 4/20 0.45
GABRG2 P18507 3/20 0.45
GABRB3 P28472 3/20 0.45
GABRA5 P31644 3/20 0.45
GABRA1 P14867 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA4 P48169 1/20 0.45
GABRA6 Q16445 1/20 0.45
MAPT P10636 2/20 0.45
GAA P10253 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2409453 0.81 KDM4E (0.66) KDM4EMAPK1KMT2AL3MBTL1GLP1R
SCHEMBL29093592 0.80 KMO (0.53) KMT2AMAPT
SCHEMBL17601553 0.80 GLP1R (0.51) KDM4EKMT2AALOX15GLP1RTARBP2
SCHEMBL1285015 0.80 TSHR (0.59) KDM4EMAPK1KMT2AL3MBTL1ALOX15
SCHEMBL28343060 0.80 GLP1R (0.51) KDM4EKMT2AL3MBTL1ALOX15GLP1R
SCHEMBL28343036 0.80 GLP1R (0.51) KDM4EKMT2AL3MBTL1ALOX15GLP1R
SCHEMBL27613559 0.79 CYP1A2 (0.54) KDM4EALOX15GABRA2GABRB2MAPT
SCHEMBL3691673 0.79 GLP1R (0.50) KDM4EKMT2AALOX15GLP1RTARBP2
SCHEMBL13310731 0.79 ALOX15 (0.49) KDM4EKMT2AALOX15MAPTRAB9A
SCHEMBL31443282 0.79 SMN1; SMN2 (0.51) KDM4EMAPK1KMT2AL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R KDM4E 2605/4885MAPK1 999/4885KMT2A 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.